

REMARKS

The Office considered the amendment filed on May 21, 2004, to be non-responsive. This Amendment cancelled pending claims 1-72 and introduced new claims 73-87, which were drawn to a method of generating an immune response. The Office considered the new claims not to read on previously elected Group IV, which is drawn to a composition comprising an antibody that binds a 85P1B3-related protein.

Applicants hereby cancel claims 73-87, without prejudice, and introduce new claims 88-98, which are drawn to an antibody or fragment thereof that binds to a 85P1B3 protein. Applicants submit that these new claims fall within the scope of the previously elected subject matter. As such, this supplemental response completes the previous response and addresses all issues raised by in the outstanding Office Action. Accordingly, reconsideration is respectfully requested.

CONCLUSION

Applicants have by way of amendments and remarks presented herein, made a sincere effort to overcome rejections and address all issues that were raised in this Office Action. Accordingly, reconsideration and allowance of the pending claims is respectfully requested. If it is determined that a telephone conversation would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 511582002800.

Dated: July 2, 2004

Respectfully submitted,

By 

James J. Mullen III, Ph.D.

Registration No.: 44,957

MORRISON & FOERSTER LLP

3811 Valley Centre Drive, Suite 500

San Diego, CA 92130

(858) 720-7940